Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Dec 23;302(24):2663-70.
doi: 10.1001/jama.2009.1913.
Collaborators, Affiliations
- PMID: 20040554
- PMCID: PMC2832285
- DOI: 10.1001/jama.2009.1913
Randomized Controlled Trial
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial
Beth E Snitz et al. JAMA. 2009.
Abstract
Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.
Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.
Design, setting, and participants: The Ginkgo Evaluation of Memory (GEM) study, a randomized, double-blind, placebo-controlled clinical trial of 3069 community-dwelling participants aged 72 to 96 years, conducted in 6 academic medical centers in the United States between 2000 and 2008, with a median follow-up of 6.1 years.
Intervention: Twice-daily dose of 120-mg extract of G. biloba (n = 1545) or identical-appearing placebo (n = 1524).
Main outcome measures: Rates of change over time in the Modified Mini-Mental State Examination (3MSE), in the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog), and in neuropsychological domains of memory, attention, visual-spatial construction, language, and executive functions, based on sums of z scores of individual tests.
Results: Annual rates of decline in z scores did not differ between G. biloba and placebo groups in any domains, including memory (0.043; 95% confidence interval [CI], 0.034-0.051 vs 0.041; 95% CI, 0.032-0.050), attention (0.043; 95% CI, 0.037-0.050 vs 0.048; 95% CI, 0.041-0.054), visuospatial abilities (0.107; 95% CI, 0.097-0.117 vs 0.118; 95% CI, 0.108-0.128), language (0.045; 95% CI, 0.037-0.054 vs 0.041; 95% CI, 0.033-0.048), and executive functions (0.092; 95% CI, 0.086-0.099 vs 0.089; 95% CI, 0.082-0.096). For the 3MSE and ADAS-Cog, rates of change varied by baseline cognitive status (mild cognitive impairment), but there were no differences in rates of change between treatment groups (for 3MSE, P = .71; for ADAS-Cog, P = .97). There was no significant effect modification of treatment on rate of decline by age, sex, race, education, APOE*E4 allele, or baseline mild cognitive impairment (P > .05).
Conclusion: Compared with placebo, the use of G. biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.
Trial registration: clinicaltrials.gov Identifier: NCT00010803.
Figures
Figure
Flow of Participants Through the Ginkgo Evaluation of Memory Study and Longitudinal Cognitive Decline Analysis
Comment in
- Ginkgo biloba and cognitive decline.
Feng L. Feng L. JAMA. 2010 Apr 21;303(15):1477; author reply 1477-8. doi: 10.1001/jama.2010.434. JAMA. 2010. PMID: 20407051 No abstract available.
Similar articles
- Ginkgo biloba for prevention of dementia: a randomized controlled trial.
DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD; Ginkgo Evaluation of Memory (GEM) Study Investigators. DeKosky ST, et al. JAMA. 2008 Nov 19;300(19):2253-62. doi: 10.1001/jama.2008.683. JAMA. 2008. PMID: 19017911 Free PMC article. Clinical Trial. - Ginkgo biloba for cognitive impairment and dementia.
Birks J, Grimley EV, Van Dongen M. Birks J, et al. Cochrane Database Syst Rev. 2002;(4):CD003120. doi: 10.1002/14651858.CD003120. Cochrane Database Syst Rev. 2002. PMID: 12519586 Updated. Review. - Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study.
Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, Carlson MC, Yasar S, Dekosky S, Burke GL. Bettermann K, et al. J Stroke Cerebrovasc Dis. 2012 Aug;21(6):436-44. doi: 10.1016/j.jstrokecerebrovasdis.2010.11.002. Epub 2011 Jan 14. J Stroke Cerebrovasc Dis. 2012. PMID: 21236699 Free PMC article. Clinical Trial. - Ginkgo biloba for cognitive impairment and dementia.
Birks J, Grimley Evans J. Birks J, et al. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003120. doi: 10.1002/14651858.CD003120.pub2. Cochrane Database Syst Rev. 2007. PMID: 17443523 Updated. Review.
Cited by
- Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia.
Koch M, DeKosky ST, Goodman M, Sun J, Furtado JD, Fitzpatrick AL, Mackey RH, Cai T, Lopez OL, Kuller LH, Mukamal KJ, Jensen MK. Koch M, et al. JAMA Netw Open. 2020 Jul 1;3(7):e209250. doi: 10.1001/jamanetworkopen.2020.9250. JAMA Netw Open. 2020. PMID: 32648923 Free PMC article. - The impact of falls on activities of daily living in older adults: A retrospective cohort analysis.
Adam CE, Fitzpatrick AL, Leary CS, Ilango SD, Phelan EA, Semmens EO. Adam CE, et al. PLoS One. 2024 Jan 3;19(1):e0294017. doi: 10.1371/journal.pone.0294017. eCollection 2024. PLoS One. 2024. PMID: 38170712 Free PMC article. - The price of progress: Funding and financing Alzheimer's disease drug development.
Cummings J, Reiber C, Kumar P. Cummings J, et al. Alzheimers Dement (N Y). 2018 Jun 13;4:330-343. doi: 10.1016/j.trci.2018.04.008. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 30175227 Free PMC article. - Effect of the Mediterranean diet and probiotic supplementation in the management of mild cognitive impairment: Rationale, methods, and baseline characteristics.
Cardelo MP, Corina A, Leon-Acuña A, Quintana-Navarro GM, Alcala-Diaz JF, Rangel-Zuñiga OA, Camargo A, Conde-Gavilan C, Carmona-Medialdea C, Vallejo-Casas JA, Carmona-Asenjo E, Ochoa-Sepulveda JJ, Aguera-Morales E, Delgado-Lista J, Katsiki N, Lopez-Miranda J, Perez-Jimenez F, Yubero-Serrano EM, Perez-Martínez P. Cardelo MP, et al. Front Nutr. 2022 Dec 8;9:1037842. doi: 10.3389/fnut.2022.1037842. eCollection 2022. Front Nutr. 2022. PMID: 36570150 Free PMC article. - Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update.
Cenini G, Voos W. Cenini G, et al. Front Pharmacol. 2019 Aug 23;10:902. doi: 10.3389/fphar.2019.00902. eCollection 2019. Front Pharmacol. 2019. PMID: 31507410 Free PMC article. Review.
References
- Barnes PM, Bloom B, Nahin RL. Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007. US Dept of Health and Human Services; Washington, DC: 2008. National Health Statistics Reports. - PubMed
- Huang S-Y, Jeng C, Kao S-C, Yu JJ-H, Liu D-Z. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr. 2004;23(4):615–621. - PubMed
- Chen X, Salwinski S, Lee TJ. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol. 1997;24(12):958–959. - PubMed
- Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761) J Mol Cell Cardiol. 1997;29(2):733–742. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50AG05133/AG/NIA NIH HHS/United States
- U01 AT000162/AT/NCCIH NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- U01 AT000162-09/AT/NCCIH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous